Immunosuppression and monocyte subsets

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 143-153

  Rogacev, Kyrill S ^a   Zawada, Adam M ^a   Hundsdorfer, Johanna ^a   Achenbach, Marina ^a   Held, Gerhard ^a   Fliser, Danilo ^a   Heine, Gunnar H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CD14; CD16; immunosuppression; monocyte; transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CD14 ANTIGEN; CD16 ANTIGEN; CD34 ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR2; CYCLOSPORIN A; DEXAMETHASONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN ENG; PROTEIN TEK; RAPAMYCIN; STEROID; TACROLIMUS; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; BODY MASS; CELL COUNT; CELL DIFFERENTIATION; CELL LINE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; KIDNEY AUTOTRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MONOCYTOSIS; MONOTHERAPY; PROTEIN EXPRESSION; STEADY STATE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CELL CULTURE; CLASSIFICATION; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RENAL INSUFFICIENCY, CHRONIC;

ANTIGENS, CD; CELLS, CULTURED; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CELL SURFACE; RENAL INSUFFICIENCY, CHRONIC; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84922430772     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu315     Document Type: Article

References (32)

1. Wyburn KR, Jose MD, Wu H et al. The role of macrophages in allograft rejection. Transplantation 2005; 80: 1641-1647
2. Xu H, Dhanireddy KK, Kirk AD. Human monocytes as intermediaries between allogeneic endothelial cells and allospecific T cells: a role for direct scavenger receptor-mediated endothelial membrane uptake in the initiation of alloimmunity. J Immunol 2006; 176: 750-761
3. Girlanda R, Kleiner DE, Duan Z et al. Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am J Transplant 2008; 8: 600-607
4. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005; 68: 1866-1874
5. Hoffmann U, Bergler T, Segerer S et al. Impact of chemokine receptor CX3CR1 in human renal allograft rejection. Transpl Immunol 2010; 23: 204-208
6. Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-e80
7. Steppich B, Dayyani F, Gruber R et al. Selective mobilization of CD14(+) CD16(+) monocytes by exercise. Am J Physiol Cell Physiol 2000; 279: C578-C586
8. Zawada AM, Rogacev KS, Rotter B et al. SuperSAGE evidence for CD14++ CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-e61
9. Nahrendorf M, Swirski FK. Monocyte and macrophage heterogeneity in the heart. Circ Res 2013; 112: 1624-1633
10. Rogacev KS, Seiler S, Zawada AM et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92
11. Rogacev KS, Ziegelin M, Ulrich C et al. Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcome. Nephrol Dial Transplant 2009; 24: 3480-3486
12. Rogacev KS, Cremers B, Zawada AM et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-1520
13. Rogacev KS, Zawada AM, Emrich I et al. Lower Apo A-I and lower HDLC levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in CKD. Arterioscler Thromb Vasc Biol 2014; 34: 2120-2127
14. Swirski FK, Wildgruber M, Ueno T et al. Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. J Clin Invest 2010; 120: 2627-2634
15. Schiopu A, Nadig SN, Cotoi OS et al. Inflammatory Ly-6C(hi) monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients. Atherosclerosis 2012; 223: 291-298
16. Fildes JE, Shaw SM, Mitsidou A et al. HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. Transpl Immunol 2008; 19: 152-157
17. Ulrich C, Heine GH, Gerhart MK et al. Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. Am J Transplant 2008; 8: 103-110
18. Fell LH, Zawada AM, Rogacev KS et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014; 29: 809-822
19. Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590
20. Meier-Kriesche HU, Schold JD, Srinivas TR et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383
21. Park WD, Griffin MD, Cornell LD et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997
22. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120-129
23. Kitchens WH, Chase CM, Uehara S et al. Macrophage depletion suppresses cardiac allograft vasculopathy in mice. Am J Transplant 2007; 7: 2675-2682
24. Yoshino T, Nakase H, Minami N et al. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-Analysis. Dig Liver Dis 2014; 46: 219-226
25. Combadiere C, Potteaux S, Rodero M et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008; 117: 1649-1657
26. Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol 2006; 80: 1156-1164
27. Cros J, Cagnard N, Woollard K et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-386
28. Dayyani F, Joeinig A, Ziegler-Heitbrock L et al. Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and lymphoma. J Leukoc Biol 2004; 75: 207-213
29. Stec M, Weglarczyk K, Baran J et al. Expansion and differentiation of CD14+CD16() and CD14+ +CD16+ human monocyte subsets from cord blood CD34+ hematopoietic progenitors. J Leukoc Biol 2007; 82: 594-602
30. Zawada AM, Rogacev KS, Schirmer SH et al. Monocyte heterogeneity in human cardiovascular disease. Immunobiology 2012; 217: 1273-1284
31. Luan FL, Steffick DE, Ojo AO. Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int 2009; 76: 825-830
32. Getts DR, Terry RL, Getts MT et al. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med 2014; 6: 219ra7